Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | -3.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.73% |
| Mar 31, 2026 | 125.00% |
| Dec 31, 2025 | 60.16% |
| Sep 30, 2025 | 43.99% |
| Jun 30, 2025 | 57.89% |
| Mar 31, 2025 | -50.27% |
| Dec 31, 2024 | 96.36% |
| Sep 30, 2024 | -25.47% |
| Jun 30, 2024 | -64.03% |
| Mar 31, 2024 | 204.07% |
| Dec 31, 2023 | -13.64% |
| Sep 30, 2023 | 114.57% |
| Jun 30, 2023 | 30.05% |
| Mar 31, 2023 | -209.14% |
| Dec 31, 2022 | 3,304.76% |
| Sep 30, 2022 | 59.87% |
| Jun 30, 2022 | 33.82% |
| Mar 31, 2022 | -146.39% |
| Dec 31, 2021 | -95.56% |
| Sep 30, 2021 | 402.94% |